Independent Financial Group LLC Acquires Shares of 1,936 Labcorp Holdings Inc. $LH

Independent Financial Group LLC bought a new position in shares of Labcorp Holdings Inc. (NYSE:LH) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 1,936 shares of the medical research company’s stock, valued at approximately $517,000.

A number of other large investors have also recently modified their holdings of LH. Victory Capital Management Inc. lifted its position in shares of Labcorp by 103.1% during the 4th quarter. Victory Capital Management Inc. now owns 5,356,825 shares of the medical research company’s stock worth $1,343,922,000 after buying an additional 2,719,475 shares during the last quarter. Boston Partners bought a new position in Labcorp in the fourth quarter valued at about $480,271,000. Norges Bank acquired a new position in Labcorp during the fourth quarter worth about $248,006,000. Wellington Management Group LLP lifted its holdings in shares of Labcorp by 15.9% in the third quarter. Wellington Management Group LLP now owns 2,105,791 shares of the medical research company’s stock worth $604,488,000 after acquiring an additional 289,029 shares during the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Labcorp by 79.1% in the third quarter. Marshall Wace LLP now owns 623,550 shares of the medical research company’s stock worth $178,996,000 after acquiring an additional 275,454 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a report on Friday, May 8th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Labcorp in a research report on Wednesday, April 8th. Robert W. Baird boosted their target price on shares of Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Bank of America upped their price target on shares of Labcorp from $300.00 to $320.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Nine research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, Labcorp has an average rating of “Moderate Buy” and an average target price of $314.40.

Insider Buying and Selling at Labcorp

In other news, EVP Bryan T. Vaughn sold 234 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The stock was sold at an average price of $286.19, for a total transaction of $66,968.46. Following the completion of the transaction, the executive vice president directly owned 6,746 shares in the company, valued at $1,930,637.74. This trade represents a 3.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the transaction, the chief executive officer directly owned 107,234 shares in the company, valued at approximately $27,291,053. This represents a 5.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 6,991 shares of company stock worth $1,796,696. Insiders own 0.84% of the company’s stock.

Labcorp Trading Up 3.2%

Shares of NYSE LH opened at $290.47 on Friday. The firm has a 50 day moving average price of $268.46 and a two-hundred day moving average price of $268.90. The stock has a market cap of $23.82 billion, a P/E ratio of 25.73, a price-to-earnings-growth ratio of 1.87 and a beta of 0.89. Labcorp Holdings Inc. has a 52-week low of $244.52 and a 52-week high of $298.45. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 EPS for the quarter, topping analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter in the previous year, the business earned $3.84 earnings per share. Labcorp’s revenue was up 5.8% compared to the same quarter last year. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. As a group, equities analysts forecast that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be issued a dividend of $0.72 per share. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 annualized dividend and a yield of 1.0%. Labcorp’s payout ratio is presently 25.51%.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.